指南与共识肝病消化道出血

AGA临床实践更新:肝硬化中的凝血管理

AGA Clinical Practice Update: Coagulation in Cirrhosis.
指南 / 共识 · Gastroenterology · 2019-04-12

本专家综述由AGA研究所临床实践更新委员会和AGA理事会委托,旨在评估肝硬化凝血机制改变的数据,指导凝血检测及抗凝与促凝药物的合理使用。基于最佳实践建议,涵盖全局凝血检测、输血阈值、血小板生成素激动剂、凝血酶原复合物、抗纤溶治疗及抗凝策略等。

要点

  • 低风险腹腔穿刺、胸腔穿刺及常规内镜下曲张静脉套扎前,不常规纠正血小板减少和凝血障碍。
  • 活动性出血或高风险操作输血阈值:血细胞比容≥25%、血小板>50,000、纤维蛋白原>120 mg/dL;不推荐常规纠正INR。
  • 直接口服抗凝药在稳定肝硬化患者中相对安全有效,但晚期肝病需进一步研究。

核心结论

  • 肝硬化患者凝血管理需基于最佳实践建议,避免不必要的血制品输注,合理使用抗凝与促凝药物。

研究设计与样本

  • 由AGA研究所临床实践更新委员会和AGA理事会委托并批准的专家综述,基于肝硬化凝血领域最具影响力的文献制定最佳实践建议,并经所有作者同意。

主要发现

  • 全局凝血检测如旋转血栓弹力测定、血栓弹力图、声流变学及凝血酶生成可能最终用于评估肝硬化患者凝血,但目前缺乏经过验证的目标水平。
  • 低风险腹腔穿刺、胸腔穿刺及常规内镜下曲张静脉套扎前,临床医生通常不应常规纠正血小板减少和凝血障碍。
  • 血制品应谨慎使用,因其增加门静脉压力并带来输血相关循环超负荷、输血相关急性肺损伤、感染传播、同种免疫和/或输血反应风险。
  • 活动性出血或高风险操作的输血阈值:血细胞比容≥25%、血小板计数>50,000、纤维蛋白原>120 mg/dL;常用INR纠正阈值缺乏证据支持。
  • 血小板生成素激动剂是血小板输注的良好替代,但需约10天提升血小板水平。

关键数值与推荐

  • 最佳实践建议1:全局凝血检测可能最终有作用,但目前缺乏验证的目标水平。
  • 最佳实践建议2:低风险操作前通常不应常规纠正血小板减少和凝血障碍。
  • 最佳实践建议3:血制品应谨慎使用。
  • 最佳实践建议4:活动性出血或高风险操作输血阈值:血细胞比容≥25%、血小板>50,000、纤维蛋白原>120 mg/dL;INR纠正阈值缺乏证据。
  • 最佳实践建议5:血小板生成素激动剂是血小板输注的良好替代,需约10天起效。

临床怎么用

  • 临床医生应依据最佳实践建议,在低风险操作前避免常规纠正凝血障碍,血制品使用应谨慎。
  • 活动性出血或高风险操作时考虑输血阈值:血细胞比容≥25%、血小板>50,000、纤维蛋白原>120 mg/dL。
  • 有症状的深静脉血栓及门静脉和肠系膜静脉血栓推荐全身肝素输注,但监测问题未解决。
  • 偶发门静脉和肠系膜静脉血栓的治疗取决于对移植手术复杂度与出血及跌倒风险的估计。
  • 稳定肝硬化患者使用直接口服抗凝药相对安全有效,但晚期肝病需进一步研究。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: This expert review was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership. The intent is to evaluate the current data on mechanism of altered coagulation in patients with cirrhosis, provide guidance on the use of currently available testing of the coagulation cascade, and help practitioners use anticoagulation and pro-coagulants appropriately in patients with cirrhosis. METHODS: This review is framed around the best practice points, which were derived from the most impactful publications in the area of coagulation in cirrhosis and agreed to by all authors. BEST PRACTICE ADVICE 1: Global tests of clot formation, such as rotational thromboelastometry, thromboelastography, sonorheometry, and thrombin generation, may eventually have a role in the evaluation of clotting in patients with cirrhosis, but currently lack validated target levels. BEST PRACTICE ADVICE 2: In general, clinicians should not routinely correct thrombocytopenia and coagulopathy before low-risk therapeutic paracentesis, thoracentesis, and routine upper endoscopy for variceal ligation in patients with hepatic synthetic dysfunction-induced coagulation abnormalities. BEST PRACTICE ADVICE 3: Blood products should be used sparingly because they increase portal pressure and carry a risk of transfusion-associated circulatory overload, transfusion-related acute lung injury, infection transmission, alloimmunization, and/or transfusion reactions. BEST PRACTICE ADVICE 4: The following transfusion thresholds for management of active bleeding or high-risk procedures may optimize clot formation in advanced liver disease: hematocrit ≥25%, platelet count >50,000, and fibrinogen >120 mg/dL. Commonly utilized thresholds for international normalized ratio correction are not supported by evidence. BEST PRACTICE ADVICE 5: Thrombopoietin agonists are a good alternative to platelet transfusion, but require time (about 10 days) to elevate platelet levels. BEST PRACTICE ADVICE 6: The large volume of fresh frozen plasma required to reach an arbitrary international normalized ratio target, limitations of the usual target, minimal effect on thrombin generation, and adverse effects on portal pressure limit the utility of this agent significantly. BEST PRACTICE ADVICE 7: The 4-factor prothrombin complex concentrate contains both pro- and anticoagulant factors that offer an attractive low-volume therapeutic to rebalance a disturbed hemostatic system. However, dosage is, in part, based on international normalized ratio, which is problematic in cirrhosis, and published experience in liver disease is limited. BEST PRACTICE ADVICE 8: Anti-fibrinolytic therapy may be considered in patients with persistent bleeding from mucosal oozing or puncture wound bleeding consistent with impaired clot integrity. Both ε-aminocaproic acid and tranexamic acid inhibit clot dissolution. Neither is believed to generate a hypercoagulable state, although both may exacerbate pre-existing thrombi. BEST PRACTICE ADVICE 9: Desmopressin releases von Willebrand factor as its primary hemostatic mechanism. As this factor is usually elevated in cirrhosis, the agent lacks a sound evidence-based foundation, but may be useful in patients with concomitant renal failure. BEST PRACTICE ADVICE 10: Systemic heparin infusion is recommended for symptomatic deep vein thrombosis and portal and mesenteric vein thrombosis, but there are unresolved issues regarding monitoring with both the anti-Xa assay and the partial thromboplastin time due to cirrhosis-related antithrombin deficiency (heparin cofactor). BEST PRACTICE ADVICE 11: Treatment of incidental portal and mesenteric vein thrombosis depends on estimated impact on transplantation surgical complexity vs risks of bleeding and falls. Therapy with low-molecular-weight heparin, vitamin K antagonists, and direct-acting anticoagulants improve portal vein repermeation vs observation alone. BEST PRACTICE ADVICE 12: Direct-acting anticoagulants, such as the factor Xa and thrombin inhibitors, are relatively safe and effective in stable cirrhotic patients, but are in need of further study in patients with more advanced liver disease.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. O'Leary JG, Greenberg CS, Patton HM, et al. AGA Clinical Practice Update: Coagulation in Cirrhosis. Gastroenterology. 2019. PMID: 30986390. doi:10.1053/j.gastro.2019.03.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。